Patrick Deelen

Drugs targeting genes linked to disease via evidence from human genetics have increased odds of approval. Approaches to prioritize such genes include genome-wide association studies (GWASs), rare variant burden tests in exome sequencing stu…

Drugs targeting genes that harbor natural variations associated with the disease the drug is in-dicated for have increased odds to be approved. Various approaches have been proposed to iden-tify likely causal genes for complex diseases, inc…